Supernus Pharmaceuticals (NASDAQ:SUPN) Announces Earnings Results, Beats Estimates By $0.25 EPS

Posted by Tech Dows on Nov 7th, 2024

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) announced its earnings results on Monday. The specialty pharmaceutical company reported $0.69 EPS for the quarter, topping the consensus estimate of $0.44 by $0.25, Briefing.com reports. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.94%. The firm had revenue of $175.70 million for the quarter, compared to the consensus estimate of $157.35 million. The business’s quarterly revenue was up 14.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.29) EPS. Supernus Pharmaceuticals updated its FY 2024 guidance to EPS.

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ SUPN traded down $0.54 during mid-day trading on Thursday, hitting $37.21. The company had a trading volume of 82,423 shares, compared to its average volume of 448,863. Supernus Pharmaceuticals has a 12 month low of $23.47 and a 12 month high of $39.37. The firm has a market cap of $2.05 billion, a P/E ratio of 35.28 and a beta of 0.86. The business’s 50-day simple moving average is $33.08 and its 200-day simple moving average is $30.59.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Cowen reissued a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Piper Sandler reissued a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Finally, StockNews.com upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th.

Get Our Latest Analysis on SUPN

Supernus Pharmaceuticals Company Profile

(Get Free Report)

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.